{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:30:25Z","timestamp":1791318625659,"version":"4.3.1"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T00:00:00Z","timestamp":1662854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To streamline drug development, the United States Food and Drug Administration (FDA) can consider the extrapolation of adult efficacy data to children when the disease and drug effects are sufficiently similar. This study explored whether the relationship between drug exposure and response for selected drugs in systemic lupus erythematosus (SLE) was sufficiently similar to support a consideration of the extrapolation of adult efficacy data to children of \u22655\u00a0years of age. An exposure\u2013response analysis of drugs used to treat SLE was conducted using published exposure versus response and efficacy versus time data. Statistical analyses included noncompartmental analysis of a drug\u2019s area under the effect curve and direct I<jats:sub>max<\/jats:sub> pharmacodynamic (PD) modeling. Six drugs were included: azathioprine, belimumab, cyclophosphamide, hydroxychloroquine, mycophenolate\/mycophenolic acid, and rituximab. For belimumab, the net change in responders at week\u00a052 (the primary end point) was nearly identical between 1 adult trial and the pediatric trial. For mycophenolate, PD modeling suggested no significant differences in exposure and SLE disease activity between adults and children. For azathioprine, cyclophosphamide, hydroxychloroquine, and rituximab the data were not sufficient to quantitatively characterize the exposure\u2013response relationship, but the clinical or pharmacologic response between children and adults was similar overall. Adult SLE data should be leveraged to guide pediatric drug development programs and identify areas with residual uncertainty regarding the effectiveness or safety of a drug in children. The degree to which efficacy extrapolation can reduce clinical trial requirements in pediatric SLE should be individualized for each new drug product, depending in part on the mechanism of action of the drug and the similarity of disease manifestations in children and adults.<\/jats:p>","DOI":"10.1002\/jcph.2139","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T10:23:40Z","timestamp":1660559020000},"page":"105-118","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure\u2013Response"],"prefix":"10.1002","volume":"63","author":[{"given":"Stephen J.","family":"Balevic","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute  Durham North Carolina USA"},{"name":"Department of Pediatrics Duke University  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Niu","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology Center for Drug Evaluation and Research (CDER) United States Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology Center for Drug Evaluation and Research (CDER) United States Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionna","family":"Green","sequence":"additional","affiliation":[{"name":"Office of Pediatric Therapeutics Office of the Commissioner United States Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"McMahon","sequence":"additional","affiliation":[{"name":"Office of Pediatric Therapeutics Office of the Commissioner United States Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Schanberg","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute  Durham North Carolina USA"},{"name":"Department of Pediatrics Duke University  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Glaser","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Transplant Medicine Office of Immunology and Inflammation Office of New Drugs CDER, FDA  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert J.","family":"Burckart","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology Center for Drug Evaluation and Research (CDER) United States Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3487"},{"key":"e_1_2_10_3_1","unstructured":"Product Label.Belimumab Injection. GlaxoSmithKline LLC.: Philadelphia PA;2021."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311416694"},{"key":"e_1_2_10_5_1","unstructured":"United States Food and Drug Administration (FDA).Pediatric science and research activities. FDA web site.https:\/\/www.fda.gov\/science\u2010research\/pediatrics\/pediatric\u2010science\u2010and\u2010research\u2010activities. Updated October 15 2021. Accessed October 25 2021."},{"key":"e_1_2_10_6_1","unstructured":"United States Food and Drug Administration (FDA).Guidance document: general clinical pharmacology considerations for pediatric studies for drugs and biological products. December2014. FDA web site.https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM425885.pdf. Accessed October 25 2021."},{"key":"e_1_2_10_7_1","unstructured":"European Medicines Agency (EMA).Reflection paper on the use of extrapolation in the development of medicines for paediatrics. EMA web site.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/adopted\u2010reflection\u2010paper\u2010use\u2010extrapolation\u2010development\u2010medicines\u2010paediatrics\u2010revision\u20101_en.pdf. Updated October 7 2018. Accessed April 19 2022."},{"key":"e_1_2_10_8_1","article-title":"Application of Bayesian statistics to support approval of intravenous belimumab in children with systemic lupus erythematosus in the United States [abstract]","volume":"71","author":"Pottackal G TJ","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008086"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.186"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew447"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180337"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213198"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4256"},{"key":"e_1_2_10_15_1","unstructured":"Product Label.Mycophenolate Mofetil. West\u2010Ward Pharmaceuticals Corporation. Eatontown NJ.2021."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-020-00983-9"},{"key":"e_1_2_10_17_1","unstructured":"Product Label.Cyclophosphamide Capsule. Cipla USA: Warren NJ;2021."},{"key":"e_1_2_10_18_1","unstructured":"Product Label.Azathioprine Tablet. Salix Pharmaceuticals: Bridgewater NJ;2021."},{"key":"e_1_2_10_19_1","unstructured":"Product Label.Rituximab Injection. Biogen and Genentech Inc.;2021."},{"key":"e_1_2_10_20_1","unstructured":"Certara.QRPEM: A New Standard of Accuracy Precision and Efficiency in NLME Population PK\/PD Methods.https:\/\/www.certara.com\/app\/uploads\/2020\/06\/WP_QRPEMPhoenixNLMEAlgorithm.pdf. Accessed June 29 2022."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030273"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217101"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"e_1_2_10_25_1","unstructured":"United States Food and Drug Administration (FDA).BLA 125370\/s\u2010064 and BLA 761043\/s\u2010007 Multi\u2010disciplinary review and evaluation: Benlysta\u00ae (belimumab) for intravenous infusion in children 5 to 17 years of age with SLE. FDA web site.https:\/\/www.fda.gov\/media\/127912\/download. Version October 12 2018. Accessed October 25 2021."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.605060"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27495"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312458466"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20397"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04733-x"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.170"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24155"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22156"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.05.002"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314547793"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-007-0694-9"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2007.126276"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140863"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2005.11.004"},{"key":"e_1_2_10_42_1","unstructured":"United States Food and Drug Administration.21 CFR Part 201. Specific requirements on content and format of labeling for human prescription drugs; revision of \u201cPediatric Use\u201d subsection in the labeling; final rule.https:\/\/www.govinfo.gov\/content\/pkg\/FR\u20101994\u201012\u201013\/html\/94\u201030238.htm. Accessed January 10 2022."},{"key":"e_1_2_10_43_1","unstructured":"Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research; United States Food and Drug Administration (FDA).Guidance document: E11 clinical investigation of medicinal products in the pediatric population. FDA web site.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/e11\u2010clinical\u2010investigation\u2010medicinal\u2010products\u2010pediatric\u2010population. Published December 2000. Accessed January 10 2022."},{"key":"e_1_2_10_44_1","unstructured":"European Medicines Agency (EMA).ICH E11(R1) step 5 guideline on clinical investigation of medicinal products in the pediatric population. EMA web site.https:\/\/www.ema.europa.eu\/en\/ich\u2010e11r1\u2010step\u20105\u2010guideline\u2010clinical\u2010investigation\u2010medicinal\u2010products\u2010pediatric\u2010population. Updated June 10 2017. Accessed October 25 2021."},{"key":"e_1_2_10_45_1","unstructured":"United States (U.S.) Department of Health and Human Services Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER).FDA web site. Guidance for industry: Providing clinical evidence of effectiveness for human drug and biological products. Published May1998.https:\/\/www.fda.gov\/media\/71655\/download. Accessed January 10 2022."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1809"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39583"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2035"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0586-5"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1232"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2019.12.035"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145445516673998"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.2139","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T22:54:19Z","timestamp":1692572059000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,11]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/jcph.2139"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2139","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,11]]},"assertion":[{"value":"2022-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}